Baylis Medical

Boston Scientific (NYSE:BSX) announced today that it closed its acquisition of Baylis Medical for $1.75 billion upfront.

On Oct. 6, 2021, Boston Scientific announced it had agreed to acquire the Canada-based company in an effort to expand its electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms, as well as a family of guidewires, sheaths and dilators used to support left heart access.

The Baylis platforms offer advanced transseptal puncture. Boston Scientific said when it announced the agreement to acquire Baylis that the company’s platforms are clinically proven to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart in procedures such as AFib ablation, left atrial appendage closure (LAAC) and mitral valve interventions.

Marlborough, Massachusetts-based Boston Scientific expects the $1.75 billion ac…

Boston Scientific (NYSE:BSX) announced today that it agreed to acquire Baylis Medical for an upfront payment of $1.75 billion.

Marlborough, Massachusetts-based Boston Scientific said in a news release that the acquisition will expand its electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms, as well as a family of guidewires, sheaths and dilators used to support left heart access.

The Baylis platforms offer advanced transseptal puncture and are clinically proven to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart, such as AFib ablation, left atrial appendage closure (LAAC) and mitral valve interventions.

Boston Scientific expects Baylis Medical to generate net sales approaching $200 million in 2022 and said the company has achieved double-digit year-over-year sales growth over each of the past five year…